Rituximab treatment of systemic lupus erythematosus associated pulmonary arterial hypertension:a new insight

Pulmonary arterial hypertension(PAH) is one of the most severe complications of systemic lupus erythematosus(SLE).Recent studies emphasized the role of T and B lymphocytes in the pathogenesis of PAH.Rituximab(RTX),not only targeting at B lymphocytes,but also been proven to affect T cells,thus could be a potential treatment for SLE-PAH.